We have shown that FOXO1 plays a role in AML leukaemogenesis as it is required for the activation of the self‐renewal program in RUNX1‐ETO CD34+ cord blood cells and thus presents a potential therapeutic target.68 Here, RUNX1T1 is linked to acute myeloid leukemia.